Scangas George A, Rathi Vinay K, Metson Ralph B, Bleier Benjamin S, Busaba Nicholas Y, Holbrook Eric H, Gray Stacey T
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA.
OTO Open. 2022 Apr 11;6(2):2473974X221092381. doi: 10.1177/2473974X221092381. eCollection 2022 Apr-Jun.
The extent to which medical management of chronic rhinosinusitis (CRS) may improve health utility value (HUV) remains unknown. We conducted a prospective pilot study to longitudinally assess HUV via the EQ-5D-5L questionnaire in patients with CRS who were receiving medical therapy but did not undergo sinus surgery. The primary study outcome was HUV at 12-month follow-up; secondary end points included HUV at baseline and 3- and 24-month follow-up. Our study enrolled 115 patients who received the following medical treatments: saline irrigations (n = 83, 72.2%), steroid sprays (n = 93, 80.9%), antihistamines (n = 64, 55.7%), steroid irrigations (n = 29, 25.2%), and oral antibiotics (n = 58, 50.4%). There was a statistically significant improvement (mean, +0.073; = .003) in HUV at 12 months (minimum clinically important difference, 0.055) as compared with baseline. However, there was no statistically significant trend in HUV over time between baseline and 24-month follow-up ( = .3033). These findings can inform cost-effectiveness research as new medical therapies for CRS emerge.
慢性鼻窦炎（CRS）的药物治疗对健康效用值（HUV）的改善程度尚不清楚。我们进行了一项前瞻性试点研究，通过EQ-5D-5L问卷对接受药物治疗但未接受鼻窦手术的CRS患者的HUV进行纵向评估。主要研究结果是12个月随访时的HUV；次要终点包括基线、3个月和24个月随访时的HUV。我们的研究招募了115名接受以下药物治疗的患者：盐水冲洗（n = 83，72.2%）、类固醇喷雾剂（n = 93，80.9%）、抗组胺药（n = 64，55.7%）、类固醇冲洗（n = 29，25.2%）和口服抗生素（n = 58，50.4%）。与基线相比，12个月时HUV有统计学显著改善（平均值，+0.073；P = .003）（最小临床重要差异，0.055）。然而，在基线和24个月随访之间，HUV随时间没有统计学显著趋势（P = .3033）。随着CRS新药物疗法的出现，这些发现可为成本效益研究提供参考。
